Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Chris Lange | May 14, 2019 at 1:25 PM EDT

Why There May Be a Big Issue With This Duchenne Muscular Dystrophy Study

Solid Biosciences shares were crumbling on Tuesday after the firm announced its first-quarter results and an update to its midstage…

Chris Lange | May 14, 2019 at 9:38 AM EDT

The Best Biotech ETFs to Buy Ahead of ASCO

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical…

Chris Lange | May 10, 2019 at 10:15 AM EDT

Big Pharma Scares Off Short Sellers

The April 30 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | May 10, 2019 at 9:50 AM EDT

Short Sellers Get Even Higher on Cannabis Stocks

The April 30 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | May 10, 2019 at 8:55 AM EDT

Short Sellers Back Off Major Biotechs

The April 30 short interest data have been compared with the previous report, and short interest in most of these…

Jon C. Ogg | May 9, 2019 at 2:10 PM EDT

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and…

Chris Lange | May 7, 2019 at 11:30 AM EDT

Why Mylan Is Getting Absolutely Crushed

Mylan released mixed first-quarter financial results before the markets opened on Tuesday, and share plunged afterward.

Chris Lange | May 7, 2019 at 9:45 AM EDT

Osmotica Pharma Makes Significant Headway With Ptosis Treatment

Osmotica Pharma shares jumped on Tuesday after the firm announced results from its late-stage trial for the treatment of ptosis…

Chris Lange | May 6, 2019 at 11:05 AM EDT

What to Expect When Mylan Reports Tuesday

Mylan is scheduled to release its first-quarter financial results before the markets open on Tuesday, and earnings are expected to…

Chris Lange | May 6, 2019 at 8:59 AM EDT

What Cytokinetics New Study Means for ALS Patients

Cytokinetics shares took a step back on Monday after the firm announced that its midstage trial for ALS failed to…

Jon C. Ogg | May 2, 2019 at 4:53 PM EDT

Is Gilead’s Stock and Revenue Free-Fall Finally Bottoming Out?

It’s no simple task for a biotech giant to try to sell itself to investors as a value stock. That…

Chris Lange | May 1, 2019 at 9:55 AM EDT

Why the FDA Is Crushing Nabriva’s UTI Treatment

Nabriva Therapeutics shares dropped sharply on Wednesday after the firm received a warning from the FDA for the New Drug…

Chris Lange | May 1, 2019 at 7:35 AM EDT

Good News for Ovarian Cancer Treatment

Hermispherx Biopharma shares shot up on Tuesday after the firm announced significant progress in its Ampligen recurrent ovarian cancer program…

Jon C. Ogg | Apr 30, 2019 at 2:25 PM EDT

Potentially Good News for Those Who Suffer From Pompe Disease

There may be some good news developing for those who suffer from Pompe Disease. Amicus Therapeutics, Inc. (NASDAQ: FOLD) has…

Paul Ausick | Apr 30, 2019 at 12:15 PM EDT

Why Pfizer Shareholders Are Smiling After Earnings

Drugmaker Pfizer beat estimates on both the top and bottom lines for the first quarter, and shares rallied after the…

1 … 99 100 101 102 103 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why There May Be a Big Issue With This Duchenne Muscular Dystrophy Study

The Best Biotech ETFs to Buy Ahead of ASCO

Big Pharma Scares Off Short Sellers

Short Sellers Get Even Higher on Cannabis Stocks

Short Sellers Back Off Major Biotechs

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

Why Mylan Is Getting Absolutely Crushed

Osmotica Pharma Makes Significant Headway With Ptosis Treatment

What to Expect When Mylan Reports Tuesday

What Cytokinetics New Study Means for ALS Patients

Is Gilead’s Stock and Revenue Free-Fall Finally Bottoming Out?

Why the FDA Is Crushing Nabriva’s UTI Treatment

Good News for Ovarian Cancer Treatment

Potentially Good News for Those Who Suffer From Pompe Disease

Why Pfizer Shareholders Are Smiling After Earnings

A Retired Couple Can Pull About $47,500 From Their IRAs This Year and Pay $0 Federal Tax. Most Leave the Free Space Unused.

Palantir vs. Salesforce: Two Visions of Enterprise AI, One Clear Winner

Social Security Said He Owed $18,000. Before Draining His Savings, He Had Three Cards to Play.

A Retired Couple Can Pull About $47,500 From Their IRAs This Year and Pay $0 Federal Tax. Most Leave the Free Space Unused.

Social Security Said He Owed $18,000. Before Draining His Savings, He Had Three Cards to Play.

Nvidia and Micron Have Driven the S&P 500’s 2026 Rally to Record Highs. History Says It’s Not Over

A Retired Couple Can Pull About $47,500 From Their IRAs This Year and Pay $0 Federal Tax. Most Leave the Free Space Unused.

Health and Healthcare Articles

All Health and Healthcare Articles

Why There May Be a Big Issue With This Duchenne Muscular Dystrophy Study

The Best Biotech ETFs to Buy Ahead of ASCO

Big Pharma Scares Off Short Sellers

Short Sellers Get Even Higher on Cannabis Stocks

Short Sellers Back Off Major Biotechs

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

Why Mylan Is Getting Absolutely Crushed

Osmotica Pharma Makes Significant Headway With Ptosis Treatment

What to Expect When Mylan Reports Tuesday

What Cytokinetics New Study Means for ALS Patients

Is Gilead’s Stock and Revenue Free-Fall Finally Bottoming Out?

Why the FDA Is Crushing Nabriva’s UTI Treatment

Good News for Ovarian Cancer Treatment

Potentially Good News for Those Who Suffer From Pompe Disease

Why Pfizer Shareholders Are Smiling After Earnings

A Retired Couple Can Pull About $47,500 From Their IRAs This Year and Pay $0 Federal Tax. Most Leave the Free Space Unused.

Palantir vs. Salesforce: Two Visions of Enterprise AI, One Clear Winner

Social Security Said He Owed $18,000. Before Draining His Savings, He Had Three Cards to Play.

Featured Reads

A Retired Couple Can Pull About $47,500 From Their IRAs This Year and Pay $0 Federal Tax. Most Leave the Free Space Unused.

Social Security Said He Owed $18,000. Before Draining His Savings, He Had Three Cards to Play.